ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,699.07
0.32%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. United Therapeutics Corporation (UTHR)

  7. United Therapeutics Corporation (UTHR) News

United Therapeutics (UTHR)

United Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:UTHR
DateTimeSourceHeadlineSymbolCompany
31/05/202412:00Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:UTHRUnited Therapeutics Corporation
30/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
28/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
22/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
20/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
16/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
16/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
16/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
14/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
14/05/202421:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
10/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
08/05/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
07/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
07/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
06/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
06/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
06/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
01/05/202411:30Business WireUnited Therapeutics Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
26/04/202419:02Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202414:00Business WireUnited Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202412:00Business WireUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024NASDAQ:UTHRUnited Therapeutics Corporation
16/04/202412:00Business WireUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
26/03/202411:00Business WireUnited Therapeutics Announces the First Comprehensive Review Publication on XenotransplantationNASDAQ:UTHRUnited Therapeutics Corporation
25/03/202411:00Business WireUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramNASDAQ:UTHRUnited Therapeutics Corporation
11/03/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
11/03/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
11/03/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
07/03/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
07/03/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
07/03/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:UTHR

Your Recent History

NASDAQ
ABACQXX
Jpmorgan Chase Bank Na P...
NASDAQ
FCXVTX
Inflation Hedge Portfoli...
BITMOT
852779
Btp Tf 0,85% Ge27 Eur
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved